The results of two studies conducted by pharmaceutical company Galderma (UK) Limited have demonstrated high patient satisfaction for the use of Azzalure (AbobotulinumtoxinA), its botulinum toxin type A product, in the glabellar complex.
The highly anticipated Aesthetics Media webinar, titled Azzalure (abobotulinum toxin type A) in Action: Key Principles and Treatment for Glabellar Lines in association with pharmaceutical company Galderma UK, is taking place on June 17 from 7pm. It will last approximately one hour.
On June 17 Aesthetics Media will be hosting its second webinar in association with pharmaceutical company Galderma UK.
The Food and Drug Administration (FDA) has approved Jeuveau, a botulinum toxin type A, for the temporary improvement in the appearance of moderate to severe glabellar lines.